Table 1.
Clonality of somatic copy-number alterations identified in distinct neuroblastoma samples during the course of disease in 9 patients.
| Patient | Risk group | # Clonal segments (% genome) | # Subclonal segments (% genome) | Biopsied samples | # Samples | MNA |
|---|---|---|---|---|---|---|
| CB1001 | HR | 100 (12%) | 3 (0.4%) | Tumour resection | 5 | Yes |
| CB1002 | HR | 644 (79%) | 105 (13%) | Diagnosis of relapse | 5 | No |
| CB1003 | HR | 54 (7%) | 57 (7%) | Neuroblastoma diagnosis + tumour resection | 10 | Yes |
| CB1004 | HR | 104 (13%) | 100 (12%) | Tumour resection | 3 | No |
| CB1005 | HR | 132 (16%) | 98 (12%) | Tumour resection | 5 | No |
| CB1007 | LR | 487 (60%) | 17 (2%) | Neuroblastoma diagnosis | 2 | No |
| CB1008 | HR | 24 (3%) | 353 (44%) | Neuroblastoma diagnosis + tumour resection | 6 | Yes |
| CB1009 | IMR | 561 (69%) | 1 (>0%) | Neuroblastoma diagnosis + tumour resection | 9 | No |
| CB1010 | HR | 247 (30%) | 33 (4%) | Diagnosis of relapse | 3 | No |
HR high-risk, IMR intermediate risk, LR low risk, MNA MYCN amplification.